Pharmaceutical intermediates

Jingkangen Biomedical provides different types of Pharmaceutical intermediates ranging from milligrams to kilograms scale (1000kg) with high quality and competitive prices.

Zoldonrasib

CAS: 2922732-54-3 Cat No: JKN03614 Purity: 98%

Note: All products of the company are for scientific research only, and do not provide products and services for any individual

Product Description

CAS 2922732-54-3 Cat No JKN03614
Name Zoldonrasib
Synonyms KRAS G12D inhibitor 18
Smiles C[C@@H](C1=C(C=C(C=N1)N2CCN(CC2)C3CC3)C4=C5CC(COC(=O)[C@@H]6CCCN(N6)C(=O)[C@H](C[C@H]7CN(CCO7)C8=CC5=C(N4CC(F)(F)F)C=C8)NC(=O)[C@H](C9CCCC9)N1CC[C@@]2(C1)CCN(C2)C(=O)[C@H]1[C@H](N1C)C1CC1)(C)C)OC
Chemical Name (2S)-2-cyclopentyl-2-[(5S)-2-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-7-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide
Formula C63H88F3N11O7 MWt 1168.4
Purity 98% Storage Store at 4--8℃
Description Zoldonrasib is an orally bioavailable covalent tri-complex inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, zoldonrasib specifically targets and non-covalently binds to cyclophilin A to form a non-covalent binary complex, which subsequently covalently and irreversibly binds to the active GTP-bound form of KRAS G12D (KRASG12D(ON)). This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This causes apoptosis in KRAS G12D-expressing tumor cells. In addition, inhibition of KRAS G12D signaling by zoldonrasib abrogates the suppressive tumor microenvironment (TME) and enhances an anti-tumor immune response which further leads to an inhibition of proliferation of KRAS G12D-expressing tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.

Product Documents

Contact Us

Tel: +86 137 2013 4139

E-mail: orders@jknbiochem.com

Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China

Get In Touch

Get In Touch

Copyright © Wuhan Jingkang en Biochem Technology Co., Ltd. All Rights Reserved | Sitemap | Powered by Reanod
Chat Wechat

Whatsapp E-mail TOP